Related references
Note: Only part of the references are listed.Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats
Y. Zhang et al.
DIABETES OBESITY & METABOLISM (2010)
A PKC-β inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats
Liping Wei et al.
MICROVASCULAR RESEARCH (2010)
Combination of the Dipeptidyl Peptidase IV Inhibitor LAF237 [(S)-1-[(3-Hydroxy-1-adamantyl)ammo]acetyl-2-cyano-pyrrolidine] with the Angiotensin II Type 1 Receptor Antagonist Valsartan [N-(1-Oxopentyl)-N-[[2′-(1H-tetrazol-5-yl)-[1,1′-biphenyl]-4-yl]methyl]-L-valine] Enhances Pancreatic Islet Morphology and Function in a Mouse Model of Type 2 Diabetes
Qianni Cheng et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells
Rosaria Piga et al.
ATHEROSCLEROSIS (2007)
Extracellular HIV-1 Tat enhances monocyte adhesion by up-regulation of ICAM-1 and VCAM-1 gene expression via ROS-dependent NF-κB activation in astrocytes
Ha Yong Song et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2007)
Oxidative stress and dysregulation of NAD(P)H oxidase and antioxidant enzymes in diet-induced metabolic syndrome
Christian K. Roberts et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Reciprocal relationships between insulin resistance and endothelial dysfunction - Molecular and pathophysiological mechanisms
JA Kim et al.
CIRCULATION (2006)
Coronary artery superoxide production and nox isoform expression in human coronary artery disease
TJ Guzik et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism
T Nyström et al.
REGULATORY PEPTIDES (2005)
(2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
D Kim et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Systemic regulation of vascular NAD(P)H oxidase activity and nox isoform expression in human arteries and veins
TJ Guzik et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease
T Nyström et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2004)
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells
N Shanmugam et al.
DIABETES (2003)
Biological actions and therapeutic potential of the glucagon-like peptides
DJ Drucker
GASTROENTEROLOGY (2002)
The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes
JM Egan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat
HA Golpon et al.
REGULATORY PEPTIDES (2001)
Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro
DG Parkes et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2001)
Share Paper
